Literature DB >> 30910868

Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.

Katherine Lee Chuy1, Evangelos K Oikonomou2, Michael A Postow1,3, Margaret K Callahan1,3, Paul B Chapman1,3, Alexander N Shoushtari1,3, Tomas G Neilan4, Michael G Fradley5, Lakshmi V Ramanathan6, Jedd D Wolchok1,3, Richard M Steingart1,3, Dipti Gupta7,3.   

Abstract

This letter to the editor describes myocarditis screening among patients undergoing combination immune checkpoint inhibitor therapy, in light of the consensus document from the Checkpoint Inhibitor Safety Working Group.

Entities:  

Year:  2019        PMID： 30910868      PMCID： PMC6516118          DOI： 10.1634/theoncologist.2019-0040

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  9 in total

1.  Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.

Authors:  Abdulrazzak Zarifa; Juan Lopez-Mattei; Nicolas L Palaskas; Cezar Iliescu; Jean-Bernard Durand; Peter Y Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Authors:  G Curigliano; D Lenihan; M Fradley; S Ganatra; A Barac; A Blaes; J Herrmann; C Porter; A R Lyon; P Lancellotti; A Patel; J DeCara; J Mitchell; E Harrison; J Moslehi; R Witteles; M G Calabro; R Orecchia; E de Azambuja; J L Zamorano; R Krone; Z Iakobishvili; J Carver; S Armenian; B Ky; D Cardinale; C M Cipolla; S Dent; K Jordan
Journal:  Ann Oncol       Date:  2020-02       Impact factor: 32.976

Review 3.  Circulating Biomarkers for Cardiotoxicity Risk Prediction.

Authors:  Fei Fei Gong; Gregory J Cascino; Gillian Murtagh; Nausheen Akhter
Journal:  Curr Treat Options Oncol       Date:  2021-04-17

Review 4.  What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.

Authors:  Marina Frayberg; Anthony Yung; Leyre Zubiri; Daniel A Zlotoff; Kerry L Reynolds
Journal:  Curr Treat Options Oncol       Date:  2021-05-26

Review 5.  Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.

Authors:  Javid Moslehi; Andrew H Lichtman; Arlene H Sharpe; Lorenzo Galluzzi; Richard N Kitsis
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 6.  Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis.

Authors:  Stéphane Ederhy; Joe-Elie Salem; Laurent Dercle; Abrar Saqif Hasan; Marion Chauvet-Droit; Pascal Nhan; Samy Ammari; Bruno Pinna; Alban Redheuil; Samia Boussouar; Stephane Champiat; Laurie Soulat-Dufour; Ariel Cohen
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

7.  Immune Checkpoint Inhibitors-Associated Cardiotoxicity.

Authors:  Chenghui Li; Sajjad A Bhatti; Jun Ying
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

8.  Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.

Authors:  Brian I Rini; Javid J Moslehi; Marc Bonaca; Manuela Schmidinger; Laurence Albiges; Toni K Choueiri; Robert J Motzer; Michael B Atkins; John Haanen; Mariangela Mariani; Jing Wang; Subramanian Hariharan; James Larkin
Journal:  J Clin Oncol       Date:  2022-03-03       Impact factor: 50.717

Review 9.  Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.

Authors:  Nicolas Palaskas; Juan Lopez-Mattei; Jean Bernard Durand; Cezar Iliescu; Anita Deswal
Journal:  J Am Heart Assoc       Date:  2020-01-21       Impact factor: 5.501
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.